Quality of life · participants with platelet dysfunction undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Red cell volume transfused (total) · participants undergoing surgery
1 finding from 1 review
Number of participants receiving a red cell transfusion (total) · participants undergoing surgery
It is very uncertain whether DDAVP changes number of participants receiving a red cell transfusion (total) compared with tranexamic acid (very low certainty).
1 finding from 1 review
Blood loss (total) · participants undergoing surgery
1 finding from 1 review
All‐cause mortality · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · participants undergoing surgery
It is very uncertain whether DDAVP changes all thrombotic events (including myocardial infarction, ischaemic… compared with tranexamic acid (very low certainty).
1 finding from 1 review
Quality of life · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Red cell volume transfused (total) · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants receiving a red cell transfusion (total) · participants undergoing surgery
DDAVP showed no clear difference in number of participants receiving a red cell transfusion (total) compared with placebo or standard care (moderate certainty).
1 finding from 1 review
Number of participants receiving a red cell transfusion (total) · participants undergoing surgery
DDAVP may leads to higher number of participants receiving a red cell transfusion (total) compared with aprotinin (low certainty).
1 finding from 1 review
Blood loss (total) · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · participants undergoing surgery
1 finding from 1 review
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · participants undergoing surgery
1 finding from 1 review
Quality of life · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood loss (total) · participants undergoing surgery
1 finding from 1 review
All‐cause mortality · participants undergoing surgery
1 finding from 1 review
All thrombotic events (including myocardial infarction, ischaemic stroke, other arterial thromboembolism, and venous thromboembolism) · participants undergoing surgery
1 finding from 1 review
Quality of life · participants undergoing surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Red cell volume transfused (total) · participants with platelet dysfunction undergoing surgery
1 finding from 1 review
Number of participants receiving a red cell transfusion (total) · participants with platelet dysfunction undergoing surgery
DDAVP showed no clear difference in number of participants receiving a red cell transfusion (total) compared with placebo or standard care: platelet dysfunction subgroup (low certainty).
1 finding from 1 review